Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 105 results:
Συντάκτης [ Τίτλος(Asc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Katsiki, Niki  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
U
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 71, 17 - 32.
Athyros, V. G., Katsiki N., & Rizzo M. (2014).  Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Curr Med Res Opin. 30(12), 2425-8.
T
Kolovou, V., Tsipis A., Mihas C., Katsiki N., Vartela V., Koutelou M., et al. (2018).  Tumor Protein p53 (TP53) Gene and Left Main Coronary Artery Disease.. Angiology. 69(8), 730-735.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Treating heart failure with preserved ejection fraction: statins could make the difference.. Angiology. 65(4), 328-9.
Katsiki, N., Koumaras C., Athyros V. G., & Karagiannis A. (2012).  Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.. Angiology. 63(1), 9-11.
Katsiki, N., Kollari E., Dardas S., Dardas P., Haidich A-B., Athyros V. G., et al. (2016).  Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study.. Open Cardiovasc Med J. 10, 64-8.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
S
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2015).  Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly.. Atherosclerosis. 238(2), 182-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Katsiki, N., Athyros V. G., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2014).  Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol. 29(4), 389-95.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2017).  Semaglutide, lipid-lowering drugs, and NAFLD.. Lancet Diabetes Endocrinol. 5(5), 329-330.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
R
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  The role of statins in the treatment of type 2 diabetes mellitus: an update.. Curr Pharm Des. 20(22), 3665-74.
Katsiki, N., Georgiadou E., & Hatzitolios A. I. (2009).  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.. Drugs. 69(11), 1417-31.
Antonopoulou, V., Karras S. N., Koufakis T., Yavropoulou M., Katsiki N., Gerou S., et al. (2019).  Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism.. J Surg Res. 245, 22-30.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Kargiotis, K., Athyros V. G., Giouleme O., Katsiki N., Katsiki E., Anagnostis P., et al. (2015).  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.. World J Gastroenterol. 21(25), 7860-8.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές